Compass Pathways to Participate in Stifel Virtual CNS Forum

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel Virtual CNS Forum at 11:30 am ET on March 18th, 2025.

A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

Compass is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250311958977/en/

Enquiries

Media: Media, [email protected]
Investors: Stephen Schultz, [email protected], +1 401 290 7324

Source: Compass Pathways plc

You May Also Be Interested In

• Compass Pathways (CMPS) PT Raised to $20 at Canaccord
• Crypto Bull Run 2026: When It Could Start, and the Bullish-by-Default Presale to Watch
• Tron Price Prediction as TRX Holds Steady While Pepeto Presale Positions for Listing